BSECompany Update28 Oct 2026 · 28 Oct 2026, 04:27 pm

Submission of the transcript of Investors'' call held on 24th October, 2026

Veerhealth Care Ltd · 511523

✦ AI SummaryResults

Veerhealth Care Ltd submitted the transcript of the investor's call held on 24th October, 2026, as per Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment7/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Veerhealth Care Ltd - 511523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Attachments (1)

📄

f9e83acf-9cd0-4699-9fa0-8fcfd3efba41.pdf

pdf

Download →
View document text
[Vaarhaalth Care Ltd. CIN : L65910MH1992PLC067632 Date: 28.10.2026 BSE Limited Department of Corporate Services P. J. Towers, Dalal Street, Fort, Mumbai- 400001. Scrip Code: 511523 Subject: Submission of Transcript of the Investor’s call held on Saturday, 24™ October, 2026 at 03.00 PM. Dear Sir/Madam, In continuation of our earlier letter dated 19" October, 2026 informing about the Video/Audio link of the Earnings Conference Call and Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company is hereby submitting transcripts of Investor’s call which was held on Saturday, 24" October, 2026 at 03:00 PM. Kindly acknowledge and take the same on records. For Veerhealth Care Ltd X Bhavin S. Shah Managing Director DIN: 03129574 Reg. Off.: 629-A Gazdar House, [st Floor, Near Kalbadevi Post Office, |.5.S. Marg, Mumbai - 400 002. Tel. No.: (022) 22018582 Fax No.: (022) 22072644 E-mail: info@veerhealthcare.net Website: www.veerhealthcare.net« www. ayuveer.com Works : Plot No. 224, Vibrant Business Park, Opp UPL, National Highway No. 8, Vapi - 396191, Gujarat \{)hVacrHcalth Care Ltd. VeerHealth Care Limited Investor Meeting 24% October, 2026 \q VeerHealth Care Ltd. k MANAGEMENT: MR. BHAVIN S. SHAH — MANAGING DIRECTOR— VEERHEALTH CARE LIMITED MR. AKASH SHAH — CHIEF FINANCIAL OFFICER— VEERHEALTH CARE LIMITED HosT: MS. VAISHNAVI VAITY — AKMIL STRATEGIC ADVISORS q VeerHealth Care Ltd. Veerhealth Care Limited October 24, 2026 Vaishnavi Vaity: Good afternoon, everyone. I'm Vaishnavi Vaity on behalf of AKMIL Strategic Advisors. T welcome you all to the investor meeting of Veer Healthcare Limited. Veer Healthcare Limited was originally incorporated on 10 July 1992 as Niyati leasing limited with a purpose to start business in investment and finance. In 2013, the management of company decided to diversify the business activities and changed its main objects to pharma sector. A new name of the company is Veer Healthcare Limited. In 2020, the company has started its operation in cosmetic ‘manufacturing. From management team, we have Mr. Bhavin S. Shah, Managing Director and Mr. Akash Shah, Chief Financial Officer. Sir, I welcome you both to the meeting. And with this, now I would like to hand over this session to Akash Sir to introduce further. Over to you, sir. ‘Thank you Akash Shah: Thank you. Good afternoon, everyone. It gives me immense pleasure to share with you the journey, achievements, and future vision of Veer Healthcare Limited, a company thaits steadily strengthening its position in the oral care and personal care manufacturing industry. Veer Healthcare Limiteids a contract manufacturing company specializing in oral care and skin care products. Our business model is built around manufacturing quality products for established customers who value reliability, consistency, regulatory compliance and long-term business relationships Our focus has been on developing long-term customer relationships rather than pursuing only short-term business opportunities. Over time, we have established relationships with customers across different market segments, including intemational institutional supply, established FMCG companies, healthcare businesses, and hospitality-related suppliers. One of the most significant achievements in our journey has been obtaining US FDA certification. For a company of our size, achieving this regulatory milestone represents a substantial accomplishment. It reflects the importance we place on manufacturing standards, quality systems, regulatory discipline, and a readiness to serve demanding markets. The US market is highly competitive and customers expect their manufacturing partners to demonstrate strong systems. For Veer Healtheare, this achievement has been more than a certification. It has strengthened our business prospects and contributed significantly to our revenue growth. It has also enhanced our ability to participate in opportunities that require a higher level of regulatory readiness We see this achievement not as the destination but as a foundation for futther progress Another important strength of Veer Healthcare is the quality and continuity of our customer relationships. One of our major customers in the United States is an institutional supplier that serves government contracts. This relationship has been particularly valuable for our business. Even during periods when market conditions have been severely affected, we have continued to receive consistent orders from this customer. This consistency provides an important degree of business visibility and demonstrates the value of serving customers whose requirements are linked to ongoing institutional demand. Page 2 of12 q VeerHealth Care Ltd. Veerhealth Care Limited October 24, 2026 We remain focused on maintaining the quality, consistency and delivery standards required to sustain and develop such relationships. Alongside our intemational business, we have also strengthened our presence in the domestic market. One of our major customers is among the oldest FMCG businesses in the Indian market. Our association with this customer has been an important contributor to our growth, providing regular orders and helping us increase our overall tumnover. Working with an established FMCG customer brings valuable experience and reinforces the importance of maintaining consistent quality and reliable supply. In addition, we receive consistent orders from a healtheare company with a network of more than 3000 retail stores across India. This relationship provides us with another important channel of business and strengthens our exposure to the healthcare and retail distribution ecosystem. One of the most encouraging indicators of our progress is our revenue performance. During the financial year 25-26, our turnover was approximately 30 crores. However, the business momentum has improved significantly. We have crossed the entire previous financial US turnover within a single quarter oft he current financial year. This is an important milestone for us. It reflects the contribution of our existing customer relationships, the business opportunities created by our regulatory capabilities, and the growing demand we are experiencing across our operations Overthe financial year 26-27, we expect to achieve a tumover of approximately 100 crores. This represents A substantial setup in our scale of operations. We recognize that achieving this target will require disciplined execution, sufficient manufacturing capacity, effective working capital ‘management, continued customer confidence, and the ability to deliver consistently We believe that the opportunities available to us are encouraging and we are focused on converting these opportunities into actual business while maintaining the quality and reliability for which we strive to be known. While our existing customers remain important to our business, we are also working to expand our customer base and develop new sources of revenue. One encouraging development is that we have received a first trial order from an Indo-Canadian company that supplies to major hotels. This opportunity opens the possibility of serving the hospitality supply chain, a segment with its own requirements for product quality, packaging, consistency, and dependable supply. If this relationship develops successfully, it could provide an additional source of revenue and further diversify our customer portfolio. Alongside this opportunity, our established relationships in the FMCG institutional supply and healthcare segments continue to provide a base for business development. Another significant step in our growing strategy was the launch of a plastic division. In the oral care and personal care industry, plastic packaging is an integral part of the final product. By developing our own plastic division, we are working towards greater integration between product manufacturing and packaging. This [Showing first 8,000 characters — download PDF for full document]